ValiRX PLC announced on Tuesday it will provide more cancer cell detection materials to UK biotech firm Amply Discovery Ltd.
The Essex, England-based life science company confirmed its subsidiary Inaphaea BioLabs Ltd has been awarded a further contract supplying cell-based assays. These will be used to analyse Amply’s small interfering RNA targets in Inaphaea’s patient derived cells with aggressive forms of breast cancer. siRNA technology is used in gene therapy and cancer treatment.
ValiRX, which focuses on early-stage cancer therapeutics and women’s health, said the deal could be worth more than £100,000 over an eight-month period.
The multiphase contract includes an upfront payment to Inaphaea of approximately £31,000. An additional payment of approximately £21,000 will be made on completion of the first phase after four months and £10,500 on completion of the remaining in-vitro phase after a further six weeks.
This follows a run of new deals for ValiRX in recent months, including contracts to supply cells to Swedish research firm BioReperia AB and to unnamed biotech companies in the US and UK.
In September, ValiRX agreed to usage of its cells in state-of-the-art organ-on-a-chip technology, and yesterday announced the shipment of Inaphaea’s first batch of patient-derived cells.
ValiRX shares were up 6.5% at 1.65 pence each on Monday morning in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
